PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug

Wang, Xingen; Yin, Wenwu; Li, Liang

doi:10.1016/j.prp.2022.154065

Cited by 3 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PELP1 is a scaffolding protein called proline, glutamate, and leucine-rich protein 1 that is an important coregulator of multiple transcription factors and nuclear receptors (Slowikowski et al, 2015;Wang et al, 2022). Recognized as a proto-oncogene, PELP1 contributes significantly to carcinogenesis and the growth of numerous cell lines.…”

Section: Pelp1mentioning

confidence: 99%

“…Recognized as a proto-oncogene, PELP1 contributes significantly to carcinogenesis and the growth of numerous cell lines. The regulation of several crucial processes, such as estrogen signaling, cell cycle progression, ribosome synthesis, and the DNA damage response, is aided by PELP1 (Wang et al, 2022). PELP1/STAT3 complexes enhanced the expression of c-myc, cyclin D1, and c-fos in a c-Src-and MAPKdependent way upon stimulation (Figure 3) (Vadlamudi et al, 2005).…”

Section: Pelp1mentioning

confidence: 99%

“…PELP1/STAT3 complexes enhanced the expression of c-myc, cyclin D1, and c-fos in a c-Src-and MAPKdependent way upon stimulation (Figure 3) (Vadlamudi et al, 2005). Moreover, a series of clinical data showed that its expression in cancer tissue differs from that in normal tissue, like breast, prostate, lung, and ovary cancers (Girard et al, 2014;Wang et al, 2022). In most malignancies, PELP1 overexpression has been linked to a worse prognosis and a larger tumor grade (Girard et al, 2014;Wang et al, 2022).…”

Section: Pelp1mentioning

confidence: 99%

“…Moreover, a series of clinical data showed that its expression in cancer tissue differs from that in normal tissue, like breast, prostate, lung, and ovary cancers (Girard et al, 2014;Wang et al, 2022). In most malignancies, PELP1 overexpression has been linked to a worse prognosis and a larger tumor grade (Girard et al, 2014;Wang et al, 2022). According to a study, node-positive and metastatic breast cancers express PELP1 two to three times more than node-negative breast tumors do (Wang et al, 2022).…”

Section: Pelp1mentioning

confidence: 99%

“…In most malignancies, PELP1 overexpression has been linked to a worse prognosis and a larger tumor grade (Girard et al, 2014;Wang et al, 2022). According to a study, node-positive and metastatic breast cancers express PELP1 two to three times more than node-negative breast tumors do (Wang et al, 2022). The mRNA and protein levels of PELP1 are increased in the context of NSCLC in comparison to those in nearby normal lung tissue (Slowikowski et al, 2015;Wang et al, 2022).…”

Section: Pelp1mentioning

confidence: 99%

See 4 more Smart Citations

Recent progress in targeted therapy for non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients has greatly improved. However, in a large number of non-small cell lung cancer cases, the carcinogenic driver is unknown. Identifying genetic alterations is critical for effective individualized therapy in NSCLC. Moreover, targeted drugs are difficult to apply in the clinic. Cancer drug resistance is an unavoidable obstacle limiting the efficacy and application of targeted drugs. This review describes the mechanisms of targeted-drug resistance and newly identified non-small cell lung cancer targets (e.g., KRAS G12C, NGRs, DDRs, CLIP1-LTK, PELP1, STK11/LKB1, NFE2L2/KEAP1, RICTOR, PTEN, RASGRF1, LINE-1, and SphK1). Research into these mechanisms and targets will drive individualized treatment of non-small cell lung cancer to generate better outcomes.

show abstract

Section: Pelp1mentioning

confidence: 99%

Section: Pelp1mentioning

confidence: 99%

Section: Pelp1mentioning

confidence: 99%

Section: Pelp1mentioning

confidence: 99%

Section: Pelp1mentioning

confidence: 99%

See 3 more Smart Citations

Recent progress in targeted therapy for non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

A hierarchical attention network integrating multi-scale relationship for drug response prediction

Wang,

Wen,

Zhang

et al. 2024

Information Fusion

View full text Add to dashboard Cite

The impact of ribosome biogenesis in cancer: from proliferation to metastasis

Hwang,

Denicourt

2024

NAR Cancer

View full text Add to dashboard Cite

The dysregulation of ribosome biogenesis is a hallmark of cancer, facilitating the adaptation to altered translational demands essential for various aspects of tumor progression. This review explores the intricate interplay between ribosome biogenesis and cancer development, highlighting dynamic regulation orchestrated by key oncogenic signaling pathways. Recent studies reveal the multifaceted roles of ribosomes, extending beyond protein factories to include regulatory functions in mRNA translation. Dysregulated ribosome biogenesis not only hampers precise control of global protein production and proliferation but also influences processes such as the maintenance of stem cell-like properties and epithelial-mesenchymal transition, contributing to cancer progression. Interference with ribosome biogenesis, notably through RNA Pol I inhibition, elicits a stress response marked by nucleolar integrity loss, and subsequent G1-cell cycle arrest or cell death. These findings suggest that cancer cells may rely on heightened RNA Pol I transcription, rendering ribosomal RNA synthesis a potential therapeutic vulnerability. The review further explores targeting ribosome biogenesis vulnerabilities as a promising strategy to disrupt global ribosome production, presenting therapeutic opportunities for cancer treatment.

show abstract

PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug

Cited by 3 publications

References 46 publications

Recent progress in targeted therapy for non-small cell lung cancer

Recent progress in targeted therapy for non-small cell lung cancer

A hierarchical attention network integrating multi-scale relationship for drug response prediction

The impact of ribosome biogenesis in cancer: from proliferation to metastasis

Contact Info

Product

Resources

About